Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model
(2002) In Antimicrobial Agents and Chemotherapy 46(6). p.2046-2048- Abstract
- The aim of the present study was to investigate the pharmacodynamics of moxifloxacin against strains of Streptococcus pyogenes with different susceptibilities to erythromycin by using an in vitro kinetic model simulating human pharmacokinetics of moxifloxacin at oral doses of 400 and 200 mg, respectively. When the different strains of S. pyogenes were exposed to the higher dose, the number of bacteria was reduced below the detection limit after 12 h and no regrowth was noted during the following 12 h. At the lower dose there was regrowth of the strains with constitutive and inducible erythromycin resistance of the MLSB phenotype. Replication assays of the regrowing bacteria indicated that the failure of moxifloxacin to kill the MLSB... (More)
- The aim of the present study was to investigate the pharmacodynamics of moxifloxacin against strains of Streptococcus pyogenes with different susceptibilities to erythromycin by using an in vitro kinetic model simulating human pharmacokinetics of moxifloxacin at oral doses of 400 and 200 mg, respectively. When the different strains of S. pyogenes were exposed to the higher dose, the number of bacteria was reduced below the detection limit after 12 h and no regrowth was noted during the following 12 h. At the lower dose there was regrowth of the strains with constitutive and inducible erythromycin resistance of the MLSB phenotype. Replication assays of the regrowing bacteria indicated that the failure of moxifloxacin to kill the MLSB strains at the lower dose was likely caused by the emergence of preexisting resistant subpopulations. Thus, the present study indicates that the presently used 400-mg dose seems to have an advantage over the lower dose in that the risk for selection of resistant subpopuIations is minimized. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/893368
- author
- Odenholt, Inga LU ; Lowdin, E ; Gustafsson, I and Cars, O
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Antimicrobial Agents and Chemotherapy
- volume
- 46
- issue
- 6
- pages
- 2046 - 2048
- publisher
- American Society for Microbiology
- external identifiers
-
- pmid:12019138
- wos:000175662800073
- scopus:0036090592
- ISSN
- 1098-6596
- DOI
- 10.1128/AAC.46.6.2046-2048.2002
- language
- English
- LU publication?
- yes
- id
- bb2b0f2e-aa44-4857-a716-70ac74a9f6df (old id 893368)
- date added to LUP
- 2016-04-01 17:03:48
- date last changed
- 2022-01-29 00:06:28
@article{bb2b0f2e-aa44-4857-a716-70ac74a9f6df,
abstract = {{The aim of the present study was to investigate the pharmacodynamics of moxifloxacin against strains of Streptococcus pyogenes with different susceptibilities to erythromycin by using an in vitro kinetic model simulating human pharmacokinetics of moxifloxacin at oral doses of 400 and 200 mg, respectively. When the different strains of S. pyogenes were exposed to the higher dose, the number of bacteria was reduced below the detection limit after 12 h and no regrowth was noted during the following 12 h. At the lower dose there was regrowth of the strains with constitutive and inducible erythromycin resistance of the MLSB phenotype. Replication assays of the regrowing bacteria indicated that the failure of moxifloxacin to kill the MLSB strains at the lower dose was likely caused by the emergence of preexisting resistant subpopulations. Thus, the present study indicates that the presently used 400-mg dose seems to have an advantage over the lower dose in that the risk for selection of resistant subpopuIations is minimized.}},
author = {{Odenholt, Inga and Lowdin, E and Gustafsson, I and Cars, O}},
issn = {{1098-6596}},
language = {{eng}},
number = {{6}},
pages = {{2046--2048}},
publisher = {{American Society for Microbiology}},
series = {{Antimicrobial Agents and Chemotherapy}},
title = {{Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model}},
url = {{http://dx.doi.org/10.1128/AAC.46.6.2046-2048.2002}},
doi = {{10.1128/AAC.46.6.2046-2048.2002}},
volume = {{46}},
year = {{2002}},
}